TTSP定义为从随机化到出现需要改变抗肿瘤疗法、进行其他临床干预或死亡的新/恶化的肺癌症状的时间,以最早发生的事件为准。PRO采用EORTC-QLQ-C30和NSCLC-SAQ进行测量;所有P值均为名义值。有意义改善的阈值是EORTC-QLQ-C30功能量表增加10分。 结果 中位随访...
研究还公布了患者报告结局(Patient-Reported Outcome),结果显示,根据 NSCLC-SAQ 的总分,与安慰剂+化疗组相比,纳武利尤单抗组患者在疾病相关症状明确恶化前的时间更长,两者中位时间为:40.0 个月(95%CI:33.6-NR)vs.31.1 个月(95%CI:25.0-...
研究还公布了患者报告结局(Patient-Reported Outcome),结果显示,根据 NSCLC-SAQ 的总分,与安慰剂+化疗组相比,纳武利尤单抗组患者在疾病相关症状明确恶化前的时间更长,两者中位时间为:40.0 个月(95%CI:33.6-NR)vs.31.1 个月(95%CI:25.0-NR)。通过重复测量的混合模型评估的 NSCLC-SAQ 评分相对于基线的总体变化被...
基线时,纳武利尤单抗组和化疗组的NSCLC-SAQ评分分别为4.98±3.26 vs. 5.07±3.34,两组肿瘤症状负担通常较低。在治疗期间完成结果评估的患者中,纳武利尤单抗组患者出现疾病相关症状明确恶化的时间(TTDD)比化疗组长,两组的中位时间分为 40.0(95%CI:33.6-NR) vs. 31.3个月(95%CI:25.0-NR)。但是,通过重复测量混合...
To date, meaningful within-patient change (MWPC) thresholds have only been proposed for NSCLC-SAQ total score. This study proposed clinically MWPC thresholds, and group-level minimal important change/difference (MIC/MID) thresholds for both improvement and worsening for the Non-Small Cell Lung ...
Qualitative Development and Content Validity of the Non–small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome In... .Qualitativedevelopment and content validity of the non-small cell lung cancersymptom assessment questionnaire (NSCLC-SAQ), a patient-reported ...
研究还公布了患者报告结局(Patient-Reported Outcome),结果显示,根据 NSCLC-SAQ 的总分,与安慰剂+化疗组相比,纳武利尤单抗组患者在疾病相关症状明确恶化前的时间更长,两者中位时间为:40.0 个月(95%CI:33.6-NR)vs.31.1 个月(95%CI:25.0-NR)。通过重复测量的混合模型评估的 NSCLC-SAQ 评分相对于基线的总体变化被...
基线时,纳武利尤单抗组和化疗组的NSCLC-SAQ评分分别为4.98±3.26 vs. 5.07±3.34,两组肿瘤症状负担通常较低。在治疗期间完成结果评估的患者中,纳武利尤单抗组患者出现疾病相关症状明确恶化的时间(TTDD)比化疗组长,两组的中位时间分为 40.0(95%CI:33.6-NR) vs. 31.3个月(95%CI:25.0-NR)。但是,通过重复测量混合...
Qualitative development and content validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument. Clin Ther. 2016;38(4):794‐810.Development of a Patient-Reported Outcome Instrument to Evaluate Symptoms of Advanced NSCLC: ...
NSCLC-SAQPROMIS PF-SFMeaningful within person changePhysical functioning and symptom severity are important factors in the experience of people with living with non-small cell lung cancer (NSCLC). This study evaluates the reliability, validity, and meaningful within-person change (MWPC) thresholds of...